Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
NCT02637323
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
81
Enrollment
INDUSTRY
Sponsor class
Conditions
Osteoarthritis of the Knee
Interventions
DRUG:
FX006 32 mg
DRUG:
TCA IR 40
Sponsor
Pacira Pharmaceuticals, Inc